Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

63.800
+3.4505.72%
Volume:2.60M
Turnover:164.52M
Market Cap:34.64B
PE:42.26
High:65.550
Open:60.350
Low:58.300
Close:60.350
52wk High:92.000
52wk Low:18.600
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:3.15
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.510
ROE:27.54%
ROA:4.97%
PB:9.02
PE(LYR):42.26
PS:5.30

Loading ...

HENLIUS Shares Climb Over 5% on Licensing Deal with Eisai for Japan Rights

Stock News
·
Feb 06

Eisai and Henlius Enter Into Exclusive Commercial License Agreement for Anti-Pd-1 Antibody Serplulimab in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech Inc - Plans 2026 Application for Es-Sclc in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech (2696) and Eisai Sign License Agreement for HANSIZHUANG in Japan

Bulletin Express
·
Feb 05

Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Stock News
·
Feb 05

Shanghai Henlius Biotech schließt Lizenzvereinbarung mit Eisai für Hansizhuang in Japan

Reuters
·
Feb 05

Shanghai Henlius Biotech - Granted Eisai Co License to Develop, Manufacture & Commercialise Hansizhuang

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech - Eisai to Pay Henlius $75 Mln Upfront Fee, Upon Execution of License Agreement

THOMSON REUTERS
·
Feb 05

BRIEF-Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai

Reuters
·
Feb 05

Shanghai Fosun Pharmaceutical Says Henlius Biotech Signs Licensing Agreement With Eisai

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech (02696) Updates on Conversion of 182.65 Million Unlisted Shares into H Shares

Bulletin Express
·
Feb 04

Shanghai Henlius Biotech (2696) Announces Completion of H Share Full Circulation

Bulletin Express
·
Feb 04

HENLIUS (02696) Finalizes Full Circulation of H Shares

Stock News
·
Feb 04

Hong Kong Stock Movement | HENLIUS (02696) Rises Nearly 5% in Early Session as HLX22 Head-to-Head Trial with Keytruda for Gastric Cancer Holds Successful US Investigator Meeting

Stock News
·
Feb 03

BUZZ-Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval

Reuters
·
Jan 28

Hong Kong Stock Movement | HENLIUS (02696) Rises Over 4% in Early Trading as HLX43 Combination Therapy Receives NMPA Approval for Clinical Trials

Stock News
·
Jan 28

Shanghai Henlius Receives Chinese Regulatory Nod to Begin Trials of HLX43 in Solid Tumors

MT Newswires Live
·
Jan 27

BRIEF-Shanghai Henlius Biotech Says Application For Clinical Trial Of HLX43 For Injection Approved

Reuters
·
Jan 27

Shanghai Henlius Biotech (2696) Obtains NMPA Approval for HLX43 Combination Therapy Trial in Advanced Solid Tumors

Bulletin Express
·
Jan 27

Shanghai Henlius Biotech - Application for Clinical Trial of Hlx43 for Injection With Hlx07 & Hansizhuang Approved

THOMSON REUTERS
·
Jan 27